Cardiometabolic Disorders News

NEW ORLEANS — In this video exclusive, James R. Gavin III, MD, PhD, talks with Jamy D. Ard, MD, about the misleading concept of metabolically healthy obesity, its effect of delaying early treatment and the benefit of small weight losses.

NEW ORLEANS — There is no single answer when it comes to determining the primary target for treating type 2 diabetes, two speakers said during a debate at the American Diabetes Association Scientific Sessions.

NEW ORLEANS — In this video exclusive, Sangeeta R. Kashyap, MD, discusses the benefits of bariatric and endoscopic procedures vs. new drugs that promise substantial weight loss and glucose lowering advancements.

NEW ORLEANS— In part one of this video exclusive, James R. Gavin III, MD, PhD, talks with Anne L. Peters, MD, about using technology in underserved populations to close the diabetes treatment gap.

NEW ORLEANS — In this video exclusive, James R. Gavin III, MD, PhD, talks with Jamy D. Ard, MD, about the role of weight loss in delaying and treating other chronic diseases.

NEW ORLEANS — Nearly all participants with obesity without diabetes assigned tirzepatide experienced at least 5% weight loss over 72 weeks compared with placebo, with at least 20% weight loss in more than half with the highest 15 mg dose.

NEW ORLEANS — Providers should use evidence-based recommendations to educate people with diabetes on misconceptions surrounding net carbohydrates, artificial sweeteners and very low-carbohydrate diets, according to a speaker.

NEW ORLEANS — Providers should take a shared decision-making approach when creating a nutrition plan for people with diabetes, according to a speaker at the American Diabetes Association Scientific Sessions.

NEW ORLEANS — Tirzepatide, a novel glucose-lowering therapy, reduced urinary albumin secretion and slowed kidney function decline for adults with type 2 diabetes and high cardiovascular risk, according to data from the SURPASS-4 trial.

In a cohort of more than 400,000 patients at high risk for CVD requiring primary prevention, less than half were taking appropriately dosed statins and less than 10% were taking nonstatin lipid-lowering therapies, researchers reported.